Tag Archives: COVID-19

Michael Frank on the Race to Fight Infectious Diseases | #HashtagFinance

CSE’s Barrington Miller chats with Michael Frank, CEO of Revive Therapeutics Ltd. (CSE:RVV) about his company’s ambitions to enter Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.

With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury
from organ transplantation.

Related links
https://revivethera.com/
https://thecse.com/en/listings/life-sciences/revive-therapeutics-ltd

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Podcasts / iHeart Radio / RSS

Dr. Ahmad Doroudian on the Potential of a COVID-19 Treatment | #HashtagFinance

Dr. Ahmad Doroudian on the Potential of a COVID-19 Treatment, Not a Cure | #HashtagFinance

The CSE’s Barrington Miller chats with Dr. Ahmad Doroudian, CEO of BetterLife Pharma Inc. (CSE:BETR), about BetterLife’s ambitions to advance on the AP-003 clinical trial programs of Altum Pharmaceuticals Inc., which includes a therapeutic pipeline consisting of three products, including AP-003, a patent-pending interferon a2b (IFNa2b) inhalation formulation. Recent studies in China and the UK have provided data that suggest the therapeutic efficacy of interferon-based treatments for COVID-19.

Here’s an overview of what’s covered in this edition of the #HashtagFinance podcast:

3:47 – What BetterLife is doing about COVID-19.

7:01 – How early their product can be used, and if it can be used for prevention.

9:32 – What BetterLife was working on before the COVID-19 pandemic.

11:32 – The differentiators between BetterLife and other companies developing COVID-19 treatments.

15:38 – Taking the treatment approach, instead of the cure approach, to COVID-19, similar to HIV.

19:58 – Phase II clinical trials, and what that means for an investor.

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Through its wholly owned subsidiary, BLife Therapeutics Inc., BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.

Related links:

Home

https://thecse.com/en/listings/life-sciences/betterlife-pharma-inc

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Podcasts / iHeart Radio / RSS

Interview with Canadian Securities Exchange CEO Richard Carleton H1 2020 Review

First of all, given that Canada remains in varying phases of lockdown due to COVID-19, how is the CSE team doing? Is everyone healthy and adjusted to working on a different basis for the time being?

Yes, everyone is in fact healthy and team morale is excellent. Right now, we have a small number of people at the head office in First Canadian Place in downtown Toronto – one IT person and usually two members of the market operations team, sometimes augmented by our software development group. They are all driving to the office rather than taking public transit.

The building has strict rules in terms of wearing face masks in public areas and distancing in the elevators, but very few people have come back to the office. We are definitely making good use of the various video-calling applications available, so teams are getting together on a daily basis for updates, to share information, and so on. And I’m pleased that people also get together for an occasional social event via video conference. I hear there may even be some games of chance involved one night of the week.

In any event, things have worked out well, and I say that knocking on wood furiously. There was obviously a lot of pressure on the trading systems in late March as Canadian markets experienced record levels of message traffic and close to record levels of trading activity. We weathered that storm quite nicely with a distributed workforce, which is very gratifying.

I will say the fact that many of our current team members were with the exchange during the global financial crisis in 2007 and 2008 really helped us respond to the various challenges, during March in particular. We knew what to look for and what the bottlenecks in the system were likely to be, and we had our eyes out for those issues. I can remember sending an email one Sunday in March saying we were going to see the market really come off the next day and thus needed to review our circuit breaker rules and have all the notices drafted in advance. We had some extra staff in the office that day just in case. We are very happy with the way our teams and all the machines we rely on rose to that particular challenge.

How did the exchange react in March when it became clear to Canadians that special measures would need to be taken to cope with COVID-19?

We were a little ahead of the curve in some respects. Many of us were at the PDAC mining conference in Toronto, and as it became apparent that a number of PDAC attendees had contracted COVID-19, we placed ourselves into voluntary self-isolation right away. As a result, we were about a week ahead of the official lockdown orders, and that put us in good shape because we had already done most of the things we would have been required to do later in the month.

As well, we have various protocols in place that have been rehearsed over the years. These anticipate the Toronto office not being available or the Vancouver office not being available and having to distribute the workload to people working remotely. We had a pretty good idea of what needed to be done.

Now, I don’t think any of us ever anticipated that we would be working like this over the course of many months, but, as I say, we had thought through this in advance and done some rehearsals, so it was really just a case of dusting off the plans and executing them.

The head office sounds quiet for the time being, but what do you anticipate in terms of gradually returning to “normal” or what you envision as your new normal? And what does Richard Carleton’s typical day look like?

People ask me what reopening is going to look like for us, and my answer is that we have been functioning throughout. We have been conducting business across all lines, whether it is trading services, market information, or listings. And as I mentioned, we are quite pleased with how everything has worked. Activity, particularly in corporate finance and listings, has been robust over the past couple of months, to say the least.

With things going as well as they have been, we are in no rush to have everyone return to the offices in Toronto and Vancouver. One of the issues is physical capacity in elevators, because we could undermine our productivity lining up to go upstairs and downstairs multiple times a day. Another issue is that many of our employees use public transit to get to the office, and people are uncomfortable with regular use of public transit right now. I don’t see that opinion changing until we get a better handle on infection rates, particularly in Toronto.

One other thing to consider is that some on our team have school-age children, and it’s not clear at this point what is going to happen in Ontario or British Columbia. Will school be back five days per week? Will it be a partial return? Will significant levels of homeschooling continue? Those are all things we have to be sensitive to when thinking about any return. My sense is we are going to be at less than full capacity, certainly at First Canadian Place, for the foreseeable future.

As for my day, it is kind of interesting. In normal times, I have a lengthy commute morning and night, and that has been replaced by walking to my basement to begin the workday. I have always been an early riser, and there has been no change there. I began using that extra time in March to give people a heads-up on what to expect each day. I scan the global financial press and other information sources every morning and send a note to all staff with thoughts on what we should expect and try to have that out no later than 7:30 in the morning. After that, my workday starts.

Before and After “COVID Hair”

 

How has this environment influenced activity at the exchange, in terms of trading, new issues, the new-issuer pipeline? Are there pluses and minuses?

We saw a tremendous amount of trading activity in March as stocks collapsed and then returned in record fashion in all markets. But financing was slow in April as a result of the uncertainty we saw in late March. There was a strong rebound across all of our business lines in late April and into May, and that has continued right through into July. We are trading on sunny July days at levels that I would have said you were crazy if you told me five years ago that these were the sorts of numbers we were going to be doing.

It may be a function of retail investors playing such a large role in our market. Even if people are getting out a bit more than before, they still have time on their hands, so they’re doing a lot of trading from home. That’s clear from the numbers we see on the turnover front.

On the corporate finance side, our numbers on a year-over-year basis are down a bit in terms of capital raised, and that really was a function of April being quiet. But there have been more deals. So, a little less money, but probably 25% or so more individual financing transactions being completed.

I think we can explain that in a few ways. One is that we obviously don’t have a long list of cannabis issuers raising large amounts of money, as was the case at this time last year. That having been said, I will point out that we are starting to see some of the big multistate operators listed on the CSE raise meaningful amounts of capital again, which is a good sign for the sector.

We are also seeing a lot of interest in precious metals exploration, energy metals, rare earths, and other commodities. Generally speaking, the amounts raised to fund exploration projects are smaller than those that the big cannabis issuers were raising in recent years.

I think through the end of May, CSE issuers had closed nearly 450 transactions, which is more than three per day. New listings have also remained healthy, with April being the exception. And the applications pipeline suggests a continued strong flow of new issues over the next few months. I am a little surprised by that, but we obviously are all very pleased.

Let’s talk about some of the numbers from the first half of 2020 as a whole, and then how the first quarter and the second quarter differed.

Trading volume in the second quarter was considerably higher than in the first quarter due to the market volatility. The corporate finance numbers are a bit skewed, because one of our US cannabis issuers raised US$300 million in January, so the total dollar amount favours the first quarter over the second. But since activity in general started to rebound in late April, the number of financings coming to market has really increased. I’d also say there has been a shift in capital formation from the cannabis space to the mining space, and good interest in technology as well.

I’ll point out again that these are not companies that will raise tens or hundreds of millions of dollars at a time. So, more money raised in the first quarter and really positive in terms of the number of transactions being completed throughout the first half.

One other important number I would highlight is IPOs completed in the first half. There were 17 IPOs across all Canadian exchanges, if you disregard CPCs and SPACs, and 15 of those took place on the CSE. Considering the slow pace of IPOs just a few years ago, this is great to see for Canadian financial markets. The majority of IPOs on the CSE were in the mining sector, which I think is also worth noting.

The creation of a senior tier at the CSE is a topic of importance to both existing and potential issuers. What can you tell us about progress toward establishing the new tier?

We are deep in discussion with the corporate finance staff from the BC and Ontario securities commissions. I am very pleased with the progress we have made to date, and we will look to publish proposed rules for the junior and senior tiers as soon as we have come to an understanding on all of the issues with the securities commissions. When we reach that stage, there will be an opportunity for members of the public, corporate finance professionals, and our issuers to provide specific comments on the proposed rule changes. Things are going well, though, and it is pretty much the biggest undertaking we have going over the course of the summer.

Can you update us on the clearing and settlement platform? That is also a huge undertaking, and it involves a wide range of parties in the financial community who do business with the exchange or for whom the exchange facilitates business.

We have identified partners who will be extremely important in executing this project as we move into the production phase. We are doing an awful lot of work on it, and this summer will be spent getting to the point where we can engage groups from the dealer and vendor communities to work with us on testing.

Let’s discuss changes in the approach to marketing, as the CSE team spent a lot of time on the road right up until the end of February. That is not the case now, nor for the foreseeable future. What new ideas emerged to help the team adapt and ensure marketing activities remained effective?

We have been very active on a variety of social media channels and have transitioned sales and marketing efforts away from individual meetings and conferences for the time being. We have replaced that with active use of Instagram broadcasts, our YouTube channel, and other online media to engage with our audience. We are at the point where we can begin to assess what is working and what is not.

The nice thing is that these activities are considerably less expensive than the kind of work we were doing before. We can fail fast on them, without significant financial impact to the organization, and direct resources to the channels where we are getting engagement. We have been doing a lot of interviews with thought leaders in emerging areas. One of the popular ones recently has been the psychedelics space.

We have also collaborated with MNP and the Aird & Berlis law firm on a series of webinars on various subjects. We’ve done psychedelics and technology, and we’ll have a cannabis update in August. We have been able to engage several hundred people at a time and are starting to see increasing numbers of subscribers to our YouTube channel and people following live on Instagram. Barrington, Phil, Grace, James Anil, Anna – everyone is getting lots of face time on these channels and engaging with different parts of our constituency.

It has been interesting and a great learning experience, and we are definitely figuring out how to better target our efforts. And it is considerably less expensive than doing things the old-fashioned way, which has been good for our bottom line.

The leadership team at a securities exchange has a somewhat unique perspective from which to observe the national business community. What are your thoughts on diversity among small-cap public companies at the management and board levels?

There is no shortage of data to suggest that management, boards of directors, and senior advisors of Canadian small-cap companies tend to be largely male and largely white, and therefore don’t reflect society more broadly. I look at the Canadian Securities Exchange, and our board and senior management team tend to fall into that category.

I am pleased that our workforce is, generally speaking, representative of the populations of Toronto and Vancouver, so it’s very diverse. And one of our challenges is identifying how we get to a greater degree of diversity in our management ranks, and on our board as well. We need to act in ways that see the Canadian Securities Exchange, in a short period of time, represent the demographic of Canada generally, and our home markets in Toronto and Vancouver more specifically.

Is there a specific role for junior capital markets to play in helping the world overcome the COVID-19 crisis?

That’s a bit of a chestnut. Small business is the engine of economic growth and employment growth and innovation in an economy. But they get to be chestnuts because there is a kernel of truth in them. We certainly see companies looking for different applications, whether they are looking for vaccines, or to lessen the severity of COVID-19 symptoms, or to anticipate outbreaks in areas at risk using combinations of data and artificial intelligence.

There are obviously many things the small-cap community is working toward in response to the epidemic. You never know where breakthroughs are going to come from. But there clearly is no shortage of entrepreneurial energy, and significant resources have been made available to help companies try to solve some of these problems.

Alan Brochstein on Surviving Cannabis Industry ‘Potholes’ in Pandemic Times

CSE’s Barrington Miller is rejoined by Alan Brochstein, founder of 420 Investor and contributor to New Cannabis Ventures, to discuss the recent issues surrounding the cannabis industry, with a specific focus on what’s happening in the United States and in the stock market.

In this wide-ranging discussion, Alan shares what he thinks are the two major “potholes” on the road to U.S. legalization (3:32), the issues presented by capital constraints in a booming business segment (7:04), the benefits for those that survive the current pandemic crisis in cannabis (10:39), and the industry’s transition from stigmatization to essential service (14:13).

Listen until the end to hear Alan’s thoughts on why banking and research are the next two issues that need to be addressed (18:39), the one mistake investors in U.S. cannabis routinely make (21:14), his biggest cannabis-related disappointment during the pandemic (22:27), the best (and worst) State cannabis rollouts (23:25), why it was important for the industry to shift away from ‘vertical integration’ (30:28), and how the industry will evolve through COVID-19.

Related Links
420 Investor
New Cannabis Ventures

Disclaimer: The views, information, or opinions expressed during the podcast are solely those of the individuals involved and do not necessarily represent those of the Canadian Securities Exchange and its employees.

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Play / RSS

Chris Moreau on How Science Fiction Has Inspired a Potentially Lung-Saving Therapy

CSE’s Barrington Miller was recently joined by Christopher Moreau, CEO of Algernon Pharmaceuticals Inc. (CSE:AGN), to discuss his company’s work to develop NP-120 (Ifenprodil) as a new therapeutic in the fight against COVID-19.

In this discussion, Chris outlines how his company focuses on drug re-purposing, a term that is widely understood through the example provided by Viagra (1:04), the important distinction between therapeutic treatments and anti-virals and vaccines (12:14), and why the “grandaddy” of all market approvals is from the USFDA (18:25).

Listen until the end to hear how the company’s name is actually inspired by the title of a science fiction novel, and how the company has a history of investigating compounds developed by the Soviet Union!

(Subsequent to this chat, Algernon announced Health Canada approval to move forward with its PH2b/3 trial here with Ifenprodil as a potential treatment for COVID-19.)

Related Link
algernonpharmaceuticals.com

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Play / RSS

Robyn Rabinovich on the Cannabis Sector’s Adjustment to Quarantine Life

CSE’s Grace Pedota recently chatted with Robyn Rabinovich, Senior Account Director, Cannabis at Hill+Knowlton Strategies, to reflect on her professional experiences in the rapidly evolving cannabis industry, dating back to the onset of the MMPR program in Canada.

In this comprehensive discussion, Robyn shares her favourite aspects of working at start-ups like CannTrust and TerrAscend (3:34), how Hill+Knowlton has uniquely positioned itself to provide B2B support to the industry (4:48), defining Cannabis 2.0 and what to expect from the 3.0 era (6:09), and her perspective on the Ontario cannabis retail situation amid COVID-19 shutdowns (11:54).

Listen until the end to hear her thoughts on how new technological applications are benefiting the cannabis industry, the prospects for consumption lounges in Toronto, and the new favourite quarantine pastime for those in the cannabis industry (hint: it’s not product consumption!)

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Play / RSS

Trevor Doerksen on the Gamification of Charitable Giving

CSE’s Anil Mall was recently joined by ePlay Digital Inc. (CSE:EPY) CEO Trevor Doerksen to discuss how his company is adapting to the recent conditions imposed by the Coronavirus, and how it inspired him to build a game that can help front line health care workers by supplying PPE (Personal Protective Equipment).

In this discussion, Trevor talks about his escape from LA during the outbreak of the COVID-19 pandemic (1:42), how current circumstances invigorated his mobile gaming project with Howie Mandel (6:43), and how he is leveraging his video game to drive donations to the #BreakoutTheMasks charity.

Listen until the end to hear more about Trevor’s unique collaboration with Howie Mandel, how the quarantine has dramatically impacted his flagship title – Big Shot, and how ePlay is adapting to release ‘quarantine-compatible’ games in the near future.

Related links:
www.eplaydigital.com
www.howiesgames.com

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Play / RSS

Evan Gappelberg on the Intersection of Ecommerce and Augmented Reality

CSE’s Barrington Miller recently caught-up with NexTech AR Solutions Corp. (CSE:NTAR) CEO Evan Gappelberg to discuss his company’s current state of operations during the Coronavirus outbreak in NYC.

During this discussion, Evan provides commentary on the (positive) impact that the pandemic is having on his business (1:19), how their AR (augmented reality) technology fits within the shop-from home-paradigm (4:43), and his prospects for the stock market and predicted timeline for recovery (15:18).

Listen to the entire show to learn about Evan’s past history with Grand Theft Auto (the video game) and his positive experience taking a company public on the Canada Securities Exchange.

Subscribe:  Apple Podcasts / Spotify / SoundCloud /
Stitcher / Google Play / RSS

Frank Holmes on the New Investment Realities in the Age of Coronavirus

CSE’s James Black recently hosted Frank Holmes, CEO and CIO at U.S. Global Investors for his second visit to the #HashtagFinance podcast.

In this discussion Frank shares his many investment observations including the global themes that are contributing to gold price speculation (1:50), why he thinks buying Bitcoin is now analogous to collecting art (7:07), and the impact of Coronavirus on recent mining and investment conferences like PDAC (14:46).

Listen until the end to hear Frank’s thoughts on how safety and technology will evolve in response to the Coronavirus and how to protect your money in a low interest rate environment.

Subscribe:  Apple Podcasts / Spotify / SoundCloud / Stitcher / Google Play / RSS